Hockin M F, Cawthern K M, Kalafatis M, Mann K G
Department of Biochemistry, The University of Vermont, College of Medicine, Burlington, Vermont 05405, USA.
Biochemistry. 1999 May 25;38(21):6918-34. doi: 10.1021/bi981966e.
The inactivation of factor Va is a complex process which includes bond cleavage (at three sites) and dissociation of the A2N.A2C peptides, with intermediate activity in each species. Quantitation of the functional consequences of each step in the reaction has allowed for understanding of the presentation of disease in individuals possessing the factor V polymorphism factor VLEIDEN. APC cleavage of membrane-bound bovine factor Va (Arg306, Arg505, Arg662) leads to the dissociation of fragments of the A2 domain, residues 307-713 (A2N.A2C + A2C-peptide), leaving behind the membrane-bound A1.LC species. Evaluation of the dissociation process by light scattering yields invariant mass loss estimates as a function of APC concentration. The rate constant for A2 fragment dissociation varies with [APC], reaching a maximal value of k = 0.028 s-1, the unimolecular rate constant for A2 domain fragment dissociation. The APC binding site resides in the factor Va light chain (LC) (Kd = 7 nM), suggesting that the membrane-bound LC.A1 product would act to sequester APC. This inhibitory interaction (LC.A1.APC) is demonstrated to exist with either purified factor Va LC or the products of factor Va inactivation. Utilizing these experimental data and the reported rates of bond cleavage, binding constants, and product activity values for factor Va partial inactivation products, a model is developed which describes factor Va inactivation and accounts for the defect in factor VLEIDEN. The model accurately predicts the rates of inactivation of factor Va and factor VaLEIDEN, and the effect of product inhibition. Modeled reaction progress diagrams and activity profiles (from either factor Va or factor VaLEIDEN) are coincident with experimentally derived data, providing a mechanistic and kinetic explanation for all steps in the inactivation of normal factor Va and the pathology associated with factor VLEIDEN.
因子Va的失活是一个复杂的过程,包括键的断裂(在三个位点)以及A2N.A2C肽段的解离,每个物种都具有中间活性。对反应中每个步骤的功能后果进行定量,有助于理解携带因子V多态性因子VLEIDEN的个体中的疾病表现。膜结合的牛因子Va(Arg306、Arg505、Arg662)被活化蛋白C(APC)切割后,会导致A2结构域片段(残基307 - 713,即A2N.A2C + A2C - 肽段)解离,留下膜结合的A1.LC物种。通过光散射评估解离过程,可得出与APC浓度相关的不变质量损失估计值。A2片段解离的速率常数随[APC]变化,达到最大值k = 0.028 s-1,即A2结构域片段解离的单分子速率常数。APC结合位点位于因子Va轻链(LC)中(Kd = 7 nM),这表明膜结合的LC.A1产物会起到隔离APC的作用。已证明这种抑制性相互作用(LC.A1.APC)在纯化的因子Va LC或因子Va失活产物中均存在。利用这些实验数据以及报道的因子Va部分失活产物的键断裂速率、结合常数和产物活性值,建立了一个模型,该模型描述了因子Va的失活并解释了因子VLEIDEN中的缺陷。该模型准确预测了因子Va和因子VaLEIDEN的失活速率以及产物抑制的效果。模拟的反应进程图和活性曲线(来自因子Va或因子VaLEIDEN)与实验得出的数据一致,为正常因子Va失活的所有步骤以及与因子VLEIDEN相关的病理学提供了机理和动力学解释。